Retrospective analysis demonstrates that tPA treatment during NMP shows no adverse effects on recipient outcomes, suggesting a safer alternative for DCD livers.
Key Points
No significant differences were found in 30-day patient and graft survival rates between the tPA-NMP-DCD and NMP-DBD groups, indicating similar outcomes.
Intraoperative transfusions were reduced, with tPA-NMP-DCD livers requiring less platelet and cryoprecipitate transfusions compared to historical DCD livers.
Observational analysis utilized data from 127 livers perfused with the OrganOx metra, including 56 DCD livers treated with tPA during NMP.
Study supports the use of tPA during NMP as a way to lower risks associated with systemic exposure for recipients of DCD livers.